Telormedix Appoints Johanna Holldack as CEO
Telormedix announced that it has appointed Dr. Johanna Holldack as its new Chief Executive Officer.
Dr. Holldack was previously Chief Executive Officer of Borean Pharma, but has also had extensive management experience in a number of other life sciences companies. Her previous posts included Chief Operation's Officer at MediGene AG in Munich, Germany, Vice President of Global Vaccines and Therapeutics at Chiron Corp. in Emeryville, USA and Head of Clinical Research and Development at German Behringwerke AG.
Dr. Holldack earned her medical degree from the Georg-August-University in Göttingen, Germany and is a Board Certified paediatrician. She spent more than a decade as a research associate and assistant professor in paediatrics and paediatric oncology and haematology at the universities of Essen and Freiburg in Germany. In addition, she has held positions as a research fellow at the Deutsche Krebshilfe and a research associate at Harvard Medical School in Boston, USA.
Other news from the department people
